<DOC>
	<DOC>NCT02969096</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of targeted cryoablation therapy for hepatic carcinoma.</brief_summary>
	<brief_title>Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma</brief_title>
	<detailed_description>A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 10-6-10minutes.</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Diagnosis of liver cancer based on histology or the current accepted radiological measures. Single Tumor size ≤5.0 cm in greatest diameter, or multiple tumor number≤3 and each tumor size≤ 3cm. Life expectancy: Greater than 3 months. Patients' liver function is Childpugh A or B. Ability to understand the study protocol and a willingness to sign a written informed consent document. Unable to receive operative surgery. Patients with other primary tumor except liver cancer. History of coagulation disorders or anemia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>